PreveCeutical Adopts Semi-Annual Financial Reporting

Rhea-AI Summary

PreveCeutical (OTCID: PRVCF) elected to adopt semi-annual financial reporting under Coordinated Blanket Order 51-933, moving from quarterly to semi-annual reporting for eligible CSE venture issuers.

The company will not file interim reports and MD&A for Q1 ending March 31, 2026 and Q3 ending September 30, 2026. PreveCeutical will continue to file audited annual financial statements (due within 120 days of December 31, 2025) and six-month interim reports (due within 60 days of June 30, 2026). The company confirms eligibility with annual revenues under $10 million and a clean 12-month continuous disclosure record.

News Market Reaction – PRVCF

%

1 alert

% News Effect

On the day this news was published, PRVCF declined NaN%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Vancouver, British Columbia--(Newsfile Corp. - April 1, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCID: PRVCF) (FSE: 18H0) (the "Company" or "PreveCeutical") announces that it has elected to rely on Coordinated Blanket Order 51-933 and move to semi-annual financial reporting ("SAR").

Coordinated Blanket Order 51-93 allows eligible venture issuers listed on the Canadian Securities Exchange (the "CSE") to voluntarily move from a quarterly to a semi-annual financial reporting framework. PreveCeutical's fiscal year ends on December 31. Under the SAR pilot program, the Company will be exempt from filing interim financial reports and related management's discussion & analysis (MD&A) for its first and third quarters:

• Interim Period: PreveCeutical will not file an interim report for the first quarter (Q1) ending March 31, 2026 and the third quarter (Q3) ending September 30, 2026; and

• Ongoing Reporting: PreveCeutical will continue to file audited annual financial statements (due within 120 days of December 31, 2025) and six-month interim financial reports (due within 60 days of June 30, 2026).

PreveCeutical confirms it meets the pilot program's eligibility criteria, which includes being a venture issuer with annual revenues of less than $10 million and maintaining a clean 12-month continuous disclosure record.

This news release is being filed pursuant to Coordinated Blanket Order 51 - 933 Exemptions to Permit Semi-Annual Reporting for Certain Venture Issuers.

About PreveCeutical

PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products. PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the Sol-gel Program; Nature Identical™ peptides for treatment of various ailments; nonaddictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury). For more information about PreveCeutical, please visit our website www.PreveCeutical.com or follow us on Twitter and Facebook.

On behalf of the Board of Directors of PreveCeutical 
Stephen Van Deventer, Chairman and Chief Executive Officer

For further information, please contact:
Stephen Van Deventer: +1 604 306 9669
Or Investor Relations ir@preveceutical.com

Neither the CSE nor any Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/290901

FAQ

What change did PreveCeutical (PRVCF) announce on April 1, 2026 about financial reporting?

PreveCeutical will move to semi-annual financial reporting, dropping quarterly interim filings for Q1 and Q3. According to the company, this is under Coordinated Blanket Order 51-933 and applies to eligible CSE venture issuers with revenues below $10 million.

Which interim reports will PreveCeutical (PRVCF) stop filing in 2026 and what are the affected dates?

PreveCeutical will not file interim reports or MD&A for Q1 ending March 31, 2026 and Q3 ending September 30, 2026. According to the company, these exemptions arise from the SAR pilot program under Order 51-933.

What financial filings will PreveCeutical (PRVCF) continue to make after adopting SAR in 2026?

The company will continue to file audited annual financial statements and six-month interim financial reports. According to the company, annual statements are due within 120 days of December 31, 2025 and six-month reports within 60 days of June 30, 2026.

Why is PreveCeutical (PRVCF) eligible for semi-annual reporting under Order 51-933?

PreveCeutical meets eligibility by being a CSE-listed venture issuer with annual revenues under $10 million and a clean 12-month disclosure record. According to the company, these criteria satisfy the SAR pilot program requirements.

How might PreveCeutical's (PRVCF) move to SAR affect investors seeking quarterly updates?

Investors will receive fewer interim filings, as Q1 and Q3 reports and MD&A will not be produced under SAR. According to the company, investors should rely on the annual and six-month filings for formal financial disclosures.